TORONTO, July 20, 2023 (GLOBE NEWSWIRE) -- The Alzheimer Society of Canada in collaboration with Brain Canada Foundation, Canadian Institutes of Health Research – Institute of Aging, and Research...
LONDON, April 28, 2021 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it has signed an exclusive license and distribution agreement with AFT Pharmaceuticals (AFT) for the commercialisation of Combogesic® IV, the US trade name of Maxigesic IV, an intravenous, opioid free post-operative pain relief medicine.
LONDON, April 28, 2021 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it has signed an exclusive license and distribution agreement with AFT Pharmaceuticals (AFT) for the commercialisation of Combogesic® IV, the US trade name of Maxigesic IV, an intravenous, opioid free post-operative pain relief medicine.
BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that its subsidiary BioSyent Pharma Inc. has signed an exclusive License and Supply Agreement (“the Agreement”) with AFT Pharmaceuticals (“AFT”, NSX: AFT, ASX: AFP) for a portfolio of new pain management products for the Canadian market. Combogesic® (also known as Maxigesic® in other countries) combines two well-known and effective medicines, acetaminophen and ibuprofen, in a single form that has been demonstrated to synergistically provide pain relief. Health Canada has recently approved the first form of Combogesic® and BioSyent Pharma Inc. intends to launch the product in 2020. Under the Agreement, BioSyent Pharma Inc. also has rights to additional forms of Combogesic® - some of which have been approved in other countries and for which it intends to seek approval in Canada.